Mesoblast Limited (NASDAQ:MESO) has earned a consensus rating of “Hold” from the eight ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $13.69.
Several brokerages recently weighed in on MESO. Chardan Capital downgraded shares of Mesoblast from a “neutral” rating to a “sell” rating and boosted their target price for the company from $5.50 to $7.50 in a research note on Friday, December 4th. Maxim Group downgraded shares of Mesoblast from a “buy” rating to a “hold” rating in a research note on Tuesday, December 22nd. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Mesoblast in a research note on Tuesday, December 15th. TheStreet downgraded shares of Mesoblast from a “c-” rating to a “d+” rating in a research note on Tuesday, October 20th. Finally, ValuEngine downgraded shares of Mesoblast from a “buy” rating to a “hold” rating in a research note on Monday, November 2nd.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Tikvah Management LLC acquired a new stake in Mesoblast during the 3rd quarter worth approximately $2,669,000. ExodusPoint Capital Management LP acquired a new stake in Mesoblast in the third quarter valued at approximately $218,000. Morgan Stanley grew its position in Mesoblast by 87.1% in the third quarter. Morgan Stanley now owns 25,396 shares of the company’s stock valued at $472,000 after acquiring an additional 11,820 shares in the last quarter. Summit X LLC acquired a new stake in shares of Mesoblast during the third quarter worth approximately $54,000. Finally, Advisory Research Inc. acquired a new stake in shares of Mesoblast during the third quarter worth approximately $846,000. 2.21% of the stock is owned by hedge funds and other institutional investors.
Mesoblast (NASDAQ:MESO) last announced its earnings results on Thursday, November 19th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.17). Mesoblast had a negative net margin of 591.00% and a negative return on equity of 18.69%. The firm had revenue of $1.31 million during the quarter, compared to analyst estimates of $119.03 million. As a group, equities analysts anticipate that Mesoblast will post -0.44 earnings per share for the current year.
Mesoblast Company Profile
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells.
Featured Story: Reverse Stock Split
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.